IL-2 autoimmune therapy (Bright Peak Therapeutics)

N/A

Report date: 2025/03/20 20:00:06

Base Information

Drug NameIL-2 autoimmune therapy (Bright Peak Therapeutics)
Drug Alias Nameengineered IL-2 cytokine therapy (Bright Peak Therapeutics)
ClassificationBiologics > Protein drugs > Recombinant protein
Mechanisms of ActionInterleukin-2 receptor agonists
TargetsInterleukin-2 receptor
Therapy Area/IndicationsAutoimmune Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySwitzerland
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesBright Peak Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesBright Peak Therapeutics Inc
Active IndicationsN/A
Inactive IndicationsAutoimmune Diseases

Other Information

ATC CodeN/A
Related LinksN/A